Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jung Won Shin

Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector. 
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.

Advertisement
Set Alert for Articles By Jung Won Shin

Latest From Jung Won Shin

Glenmark, Yuhan Partner for Ryaltris, Eyes On US Trajectory

Glenmark has kicked off 2019 with more regional deal-making, sealing an alliance for its investigational rhinitis asset with Yuhan in South Korea. But the outlook for the fixed-dose combination nasal spray also hinges on its US approval.
Commercial Deals

Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier

Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.

Deals Business Strategies

Syntekabio Aiming To Be Pharma Companion In AI-Driven Drug Development

Syntekabio is at the forefront of artificial intelligence-driven new drug development in South Korea. Its CEO Tyson Kim talks to Scrip how the genome big data and AI platform company is helping the pharma industry to develop new drugs more efficiently and rapidly.

Artificial Intelligence South Korea

Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed

2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
South Korea Outlook 2019

Celltrion Eyes Direct Global Sales To Bolster Margins, Growth

Biosimilar specialist Celltrion is aiming for the next stage of growth by setting up its own global direct sales and marketing system and through a new subcutaneous formulation of infliximab, and is looking to begin discussions with existing overseas marketing partners.

Biosimilars South Korea

Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board

Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China. 
Deals Asia Pacific
See All
Advertisement
UsernamePublicRestriction

Register